title: TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin.
abstract: Initially considered to be of natural killer (NK)-cell origin, CD4+ CD56+ blastic tumors (BTs) of skin have recently been proposed to be of dendritic cell lineage. We have previously described BTs with transformation to myelomonocytic leukemia. Here we report expression of the lymphoid proto-oncogene TCL1 in 10 (83%) of 12 BTs and in lymph node plasmacytoid dendritic cells (DC2s). TCL1 was also expressed in myelomonocytic blasts of 3 transformed BT cases but not in true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell malignancies (1 of 112, < 1%), with the exception of T-prolymphocytic leukemia (T-PLL). All BT cases were also positive for the DC2-associated marker CD123. These results further support derivation of BTs from DC2s, and demonstrate that TCL1 expression in this tumor is common to the immature blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease.
authors.affiliation: Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston 77030, USA.
authors.forename: Marco
authors.initials: M
authors.lastname: Herling
authors.forename: Michael A
authors.initials: MA
authors.lastname: Teitell
authors.forename: Rhine R
authors.initials: RR
authors.lastname: Shen
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Dan
authors.initials: D
authors.lastname: Jones
mesh_terms: D001853:Bone Marrow / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D015704:CD4 Antigens / Q000032:analysis*; D019002:CD56 Antigen / Q000032:analysis*; D003713:Dendritic Cells / Q000737:chemistry*; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D053650:Interleukin-3 Receptor alpha Subunit; D007694:Killer Cells, Natural; D007951:Leukemia, Myeloid / Q000378:metabolism; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology; D015463:Leukemia, Prolymphocytic / Q000378:metabolism; D015458:Leukemia, T-Cell / Q000378:metabolism; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D008223:Lymphoma / Q000737:chemistry; D016399:Lymphoma, T-Cell / Q000737:chemistry; D010950:Plasma Cells / Q000737:chemistry / Q000276:immunology; D017346:Protein Serine-Threonine Kinases; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D051057:Proto-Oncogene Proteins c-akt; D016185:Receptors, Interleukin-3 / Q000032:analysis; D012878:Skin Neoplasms / Q000737:chemistry* / Q000276:immunology
chemical_list: D015704:CD4 Antigens; D019002:CD56 Antigen; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D016185:Receptors, Interleukin-3; C090851:TCL1A protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt